Pituitary adenylate cyclase‐activating polypeptide targeted treatments in primary headache disorders
Annals of Clinical and Translational Neurology · 2024-07 · 11 (7) · 1654-1668
DOI: 10.1002/acn3.52119 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 18.06.2024. Verfasst von Nazia Karsan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Headache Group, The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), NIHR King's Clinical Research Facility and SLaM Biomedical Research Centre…. Hauptthemen laut MEDLINE: Pituitary Adenylate Cyclase-Activating Polypeptide. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Migraine is a complex and disabling neurological disorder. Recent years have witnessed the development and emergence of novel treatments for the condition, namely those targeting calcitonin gene‐related peptide (CGRP). However, there remains a substantial need for further treatments for those unresponsive to current therapies. Targeting pituitary adenylate cyclase‐activating polypeptide (PACAP) as a possible therapeutic strategy in the primary headache disorders has gained interest over recent years.
Methods
This review will summarize what we know about PACAP to date: its expression, receptors, roles in migraine and cluster headache biology, insights gained from preclinical and clinical models of migraine, and therapeutic scope.
Results
PACAP shares homology with vasoactive intestinal polypeptide (VIP) and is one of several vasoactive neuropeptides along with CGRP and VIP, which has been implicated in migraine neurobiology. PACAP is widely expressed in areas of interest in migraine pathophysiology, such as the thalamus, trigeminal nucleus caudalis, and sphenopalatine ganglion. Preclinical evidence suggests a role for PACAP in trigeminovascular sensitization, while clinical evidence shows ictal release of PACAP in migraine and intravenous infusion of PACAP triggering attacks in susceptible individuals. PACAP leads to dural vasodilatation and secondary central phenomena via its binding to different G‐protein‐coupled receptors, and intracellular downstream effects through cyclic adenosine monophosphate (cAMP) and phosphokinase C (PKC). Targeting PACAP as a therapeutic strategy in headache has been explored using monoclonal antibodies developed against PACAP and against the PAC1 receptor, with initial positive results.
Interpretation
Future clinical trials hold considerable promise for a new therapeutic approach using PACAP‐targeted therapies in both migraine and cluster headache.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Headache Group, The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), NIHR King's Clinical Research Facility and SLaM Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College…
- Department of Medicine, Institute of Clinical Sciences, Lund University, 221 84, Lund, Sweden.
- Department of Neurology, Albert Szent-Györgyi Medical School, and HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged, Semmelweis u. 6, Szeged, H-6725, Hungary.
- Department of Neurology, University of California, Los Angeles, California, USA.
ORCID-Profile: Peter J Goadsby
Zitieren
APA
Karsan, N., Edvinsson, L., Vecsei, L., & Goadsby, P. J. (2024). Pituitary adenylate cyclase‐activating polypeptide targeted treatments in primary headache disorders. Annals of Clinical and Translational Neurology, 11(7), 1654-1668. https://doi.org/10.1002/acn3.52119
Vancouver
Karsan N, Edvinsson L, Vecsei L, Goadsby PJ. Pituitary adenylate cyclase‐activating polypeptide targeted treatments in primary headache disorders. Annals of Clinical and Translational Neurology. 2024;11(7):1654-1668. doi:10.1002/acn3.52119
BibTeX
@article{Karsan2024,
author = {Karsan, Nazia and Edvinsson, Lars and Vecsei, Laszlo and Goadsby, Peter J},
title = {Pituitary adenylate cyclase‐activating polypeptide targeted treatments in primary headache disorders},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
volume = {11},
number = {7},
pages = {1654--1668},
doi = {10.1002/acn3.52119}
}
EUVIMED